Henri Roche

Summary

Affiliation: Institut Claudius Regaud
Country: France

Publications

  1. ncbi Inflammatory breast cancer outcome with epirubicin-based induction and maintenance chemotherapy: ten-year results from the French Adjuvant Study Group GETIS 02 Trial
    Corinne Veyret
    Department of Medical Oncology, Henri Becquerel Center, Rouen, France
    Cancer 107:2535-44. 2006
  2. ncbi Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: a pooled analysis by performance status of efficacy and safety data from 2 phase III studies
    Henri Roche
    Institut Claudius Regaud, 20 24 rue du Saint Pierre, 31052, Toulouse Cedex, France
    Breast Cancer Res Treat 125:755-65. 2011
  3. ncbi Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial
    Henri Roche
    Department of Medical Oncology, Institut Claudius Regaud, Toulouse, France
    J Clin Oncol 24:5664-71. 2006
  4. ncbi Treatment of metastatic breast cancer: second line and beyond
    H Roche
    Department of Medical Oncology, Institut Claudius Regaud, Toulouse, France
    Ann Oncol 22:1000-10. 2011
  5. ncbi Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy
    Henri Roche
    Institut Claudius Regaud, 20 24 rue du Saint Pierre, 31052 Toulouse Cedex, France
    J Clin Oncol 25:3415-20. 2007
  6. ncbi Systemic therapy of inflammatory breast cancer from high-dose chemotherapy to targeted therapies: the French experience
    Patrice Viens
    Department of Medical Oncology, Paoli Calmettes Institute, Marseille Cancer Research Center, UMR891 Inserm, IFR137, Marseille, France
    Cancer 116:2829-36. 2010
  7. ncbi A phase I dose-escalating and pharmacokinetic study of docetaxel and vinorelbine as first-line chemotherapy for metastatic breast cancer
    Jean Pierre Delord
    Institut Claudius Regaud, Toulouse, France
    Oncology 72:322-5. 2007
  8. ncbi Widespread estrogen-dependent repression of micrornas involved in breast tumor cell growth
    Gérard Maillot
    Institut National de la Sante et de la Recherche Medicale U563, Institut Claudius Regaud, and universite de Toulouse, UPS, Centre de Physiopathologie de Toulouse Purpan, Toulouse, France
    Cancer Res 69:8332-40. 2009
  9. ncbi Joint pain with aromatase inhibitors: abnormal frequency of Sjögren's syndrome
    Michel Laroche
    Service de Rhumatologie, CHU Rangueil, 1 avenue Jean Poulhes, Toulouse, France
    J Rheumatol 34:2259-63. 2007
  10. ncbi Formation of the eIF4F translation-initiation complex determines sensitivity to anticancer drugs targeting the EGFR and HER2 receptors
    Pierre Zindy
    INSERM U563, Universite Paul Sabatier, Toulouse, France
    Cancer Res 71:4068-73. 2011

Collaborators

Detail Information

Publications17

  1. ncbi Inflammatory breast cancer outcome with epirubicin-based induction and maintenance chemotherapy: ten-year results from the French Adjuvant Study Group GETIS 02 Trial
    Corinne Veyret
    Department of Medical Oncology, Henri Becquerel Center, Rouen, France
    Cancer 107:2535-44. 2006
    ....
  2. ncbi Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: a pooled analysis by performance status of efficacy and safety data from 2 phase III studies
    Henri Roche
    Institut Claudius Regaud, 20 24 rue du Saint Pierre, 31052, Toulouse Cedex, France
    Breast Cancer Res Treat 125:755-65. 2011
    ..gov identifiers: NCT00080301 and NCT00082433)...
  3. ncbi Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial
    Henri Roche
    Department of Medical Oncology, Institut Claudius Regaud, Toulouse, France
    J Clin Oncol 24:5664-71. 2006
    ....
  4. ncbi Treatment of metastatic breast cancer: second line and beyond
    H Roche
    Department of Medical Oncology, Institut Claudius Regaud, Toulouse, France
    Ann Oncol 22:1000-10. 2011
    ..It is hoped that in the near future, ongoing refinements to treatment approaches used in second-line settings and beyond will allow meaningful improvements in symptom control and survival in MBC...
  5. ncbi Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy
    Henri Roche
    Institut Claudius Regaud, 20 24 rue du Saint Pierre, 31052 Toulouse Cedex, France
    J Clin Oncol 25:3415-20. 2007
    ..This study was conducted to assess the efficacy and safety of the novel antineoplastic, the epothilone B analog ixabepilone, in patients with MBC previously treated with an adjuvant anthracycline...
  6. ncbi Systemic therapy of inflammatory breast cancer from high-dose chemotherapy to targeted therapies: the French experience
    Patrice Viens
    Department of Medical Oncology, Paoli Calmettes Institute, Marseille Cancer Research Center, UMR891 Inserm, IFR137, Marseille, France
    Cancer 116:2829-36. 2010
    ....
  7. ncbi A phase I dose-escalating and pharmacokinetic study of docetaxel and vinorelbine as first-line chemotherapy for metastatic breast cancer
    Jean Pierre Delord
    Institut Claudius Regaud, Toulouse, France
    Oncology 72:322-5. 2007
    ..We found no pharmacokinetic interaction between the two drugs. These results suggest that a pharmacodynamic interaction was the cause of the hematological toxicity and that sequential regimens should be preferably further explored...
  8. ncbi Widespread estrogen-dependent repression of micrornas involved in breast tumor cell growth
    Gérard Maillot
    Institut National de la Sante et de la Recherche Medicale U563, Institut Claudius Regaud, and universite de Toulouse, UPS, Centre de Physiopathologie de Toulouse Purpan, Toulouse, France
    Cancer Res 69:8332-40. 2009
    ....
  9. ncbi Joint pain with aromatase inhibitors: abnormal frequency of Sjögren's syndrome
    Michel Laroche
    Service de Rhumatologie, CHU Rangueil, 1 avenue Jean Poulhes, Toulouse, France
    J Rheumatol 34:2259-63. 2007
    ..With these treatments, joint pain is frequent (30% to 40%) and quite often disabling (5% to 10%). Our objective was to investigate the origin of the pain induced by the anti-aromatases...
  10. ncbi Formation of the eIF4F translation-initiation complex determines sensitivity to anticancer drugs targeting the EGFR and HER2 receptors
    Pierre Zindy
    INSERM U563, Universite Paul Sabatier, Toulouse, France
    Cancer Res 71:4068-73. 2011
    ..Together, our findings suggest that formation of the eIF4F complex may be a critical determinant of the response to anticancer drugs that target HER2 and epidermal growth factor receptor...
  11. ncbi Tipifarnib plus tamoxifen in tamoxifen-resistant metastatic breast cancer: a negative phase II and screening of potential therapeutic markers by proteomic analysis
    Florence Dalenc
    Institut Claudius Regaud, Universite Paul Sabatier, Toulouse, France
    Clin Cancer Res 16:1264-71. 2010
    ..Preclinical data suggest that FTIs could restore tamoxifen responsiveness in tamoxifen-resistant disease. Thus, combining FTIs and tamoxifen may be a promising clinical approach after relapse or progression on tamoxifen...
  12. ncbi [Critical study of our initial experience of 993 sentinel node biopsies for breast surgery]
    Pierre Martel
    Departement de Chirurgie, Institut Claudius Regaud, 20 24, rue du Pont Saint Pierre, 31052 Toulouse, France
    Bull Cancer 95:763-72. 2008
    ..Identification of sentinel node (SN) involvement predictive factors, non-sentinel node involvement predictive factors, selective prognosis of each group of patients by study of breast surgery cases with sentinel node sampling...
  13. ncbi High-dose chemotherapy for breast cancer: the French PEGASE experience
    Henri Roche
    Institut Claudius Regaud, 31052 Toulouse Cedex, France
    Cancer Control 10:42-7. 2003
    ..The French PEGASE Group was founded to perform larger and properly randomized comparative studies of this approach...
  14. ncbi A recombinant cell bioassay for measurement of overall estrogenic activity of serum: preliminary results in women with breast cancer
    Sophie Séronie-Vivien
    INSERM U563, Centre de Physiopathologie de Toulouse Purpan, Département Innovation thérapeutique et Oncologie Moléculaire, Institut Claudius Regaud, Toulouse, France
    Clin Chem Lab Med 42:889-95. 2004
    ..8568) but poor for patients (r2=0.0563). Assessment of the OEAS/E2 ratio as a prognostic and predictive factor would be of interest in clinical prospective trials involving ER+ breast cancer patients...
  15. ncbi HFS-14, a specific quality of life scale developed for patients suffering from hand-foot syndrome
    Vincent Sibaud
    Department of Dermatology, Institut Claudius Regaud, 31052 Toulouse Cedex, France
    Oncologist 16:1469-78. 2011
    ..However, there is currently no specific tool to measure QoL in patients with HFS. Objective. The objective was to develop and validate a HFS-specific QoL questionnaire (HFS-14)...
  16. ncbi Dexamethasone as a probe for vinorelbine clearance
    Florent Puisset
    EA3035, Institut Claudius-Regaud, Toulouse, France
    Br J Clin Pharmacol 60:45-53. 2005
    ..CONCLUSIONS: These results indicate that individualization of vinorelbine dose would be improved by using dexamethasone clearance rather than BSA. Dexamethasone merits further evaluation as a probe of CYP3A metabolism...
  17. ncbi An unusual case of sarcoma of the breast
    Leonardo Astudillo
    Department of Internal Medicine, University School of Medicine Purpan, Toulouse, France
    Breast J 11:74-5. 2005